Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Cash from Financing Activities: 2013-2025

Historic Cash from Financing Activities for Ocular Therapeutix (OCUL) over the last 12 years, with Sep 2025 value amounting to $10.4 million.

  • Ocular Therapeutix's Cash from Financing Activities rose 147.87% to $10.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $116.9 million, marking a year-over-year decrease of 73.18%. This contributed to the annual value of $332.1 million for FY2024, which is 95.56% up from last year.
  • According to the latest figures from Q3 2025, Ocular Therapeutix's Cash from Financing Activities is $10.4 million, which was down 89.41% from $97.8 million recorded in Q2 2025.
  • Ocular Therapeutix's Cash from Financing Activities' 5-year high stood at $321.2 million during Q1 2024, with a 5-year trough of -$1.2 million in Q1 2021.
  • Over the past 3 years, Ocular Therapeutix's median Cash from Financing Activities value was $9.6 million (recorded in 2023), while the average stood at $55.8 million.
  • Per our database at Business Quant, Ocular Therapeutix's Cash from Financing Activities tumbled by 109.07% in 2021 and then soared by 411,724.36% in 2024.
  • Ocular Therapeutix's Cash from Financing Activities (Quarterly) stood at $667,000 in 2021, then crashed by 31.33% to $458,000 in 2022, then soared by 23,517.90% to $108.2 million in 2023, then crashed by 95.83% to $4.5 million in 2024, then skyrocketed by 147.87% to $10.4 million in 2025.
  • Its last three reported values are $10.4 million in Q3 2025, $97.8 million for Q2 2025, and $4.2 million during Q1 2025.